Inhibition of COX-2 in colon cancer cell lines by celecoxib increases the nuclear localization of active p53

Cancer Research

Volumn 63, Issue 17, 2003, Pages 5239-5242

  Swamy, Malisetty V ^a   Herzog, Christopher R ^a   Rao, Chinthalapally V ^a  

^a AMERICAN HEALTH FOUNDATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELECOXIB; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; PROSTAGLANDIN A1; PROTEIN P21; PROTEIN P53;

ARTICLE; CELL NUCLEUS; CELLULAR DISTRIBUTION; COLON CANCER; COLON CARCINOGENESIS; CONTROLLED STUDY; CYTOSOL; DRUG MECHANISM; ENZYME INHIBITION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; TUMOR SUPPRESSOR GENE; ULTRAVIOLET RADIATION;

ANTINEOPLASTIC AGENTS; CELL DIVISION; CELL NUCLEUS; COLONIC NEOPLASMS; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLINS; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; CYCLOOXYGENASE INHIBITORS; HUMANS; ISOENZYMES; MEMBRANE PROTEINS; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; PROSTAGLANDINS A; PYRAZOLES; SUBCELLULAR FRACTIONS; SULFONAMIDES; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53; ULTRAVIOLET RAYS;

EID: 0141816863     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Smith, W., Garavito, R., and DeWitt, D. Prostaglandin endoperoxide H synthase (cyclooxygenase-1 and 2). J. Biol. Chem., 271: 33157-33160, 1996.
2. DuBois, R. N., Tsujii, M., Bishop, P., Awad, J. A., Makita, K., and Lanahan, A. Cloning and characterization of a growth factor-inducible cyclooxygenase gene from rat intestinal epithelial cells. Am. J. Physiol., 266: G822-G827, 1994.
3. Toketo, M. M. Cyclooxygenase-2 inhibitors in tumorigenesis part (1). J. Natl. Cancer Inst. (Bethesda), 90: 1529-1536, 1998.
4. Boojbool, S. K., Dannenberg, A. J., Chadburn, A., Martucci, C., Guo, X. J., Ramonetti, J. T., Abreu-Goris, M., Newmark, H. L., Lipkin, M. L., DeCosse, J. J., and Bertagonolli, M. M. Cyclooxygenase-2 overexpression and tumor formation are blocked by sulindac in a murine model of familial adenomatous polyposis. Cancer Res., 56: 2556-2560, 1996.
5. DuBois, R. N., Radhika, A., Reddy, B. S., and Entingh, A. J. Increased cyclooxygenase-2 levels in carcinogen-induced rat colonic tumors. Gastroenterology, 110: 1259-1262, 1996.
6. Oshima, M., Dinchuk, J. E., Kargman, S. L., Oshima, H., Hancock, B., Kwong, E., Trzaskos, J. M., Evans, J. F., and Toketo, M. M. Suppression of intestinal polyposis in APC 716 knockout mice by inhibition of cyclooxygenase-2 (COX-2). Cell, 87: 803-809, 1996.
7. Rao, C. V., Kawamori, T., Hamid, R., and Reddy, B. S. Chemoprevention of colonic aberrant crypt foci by an inducible nitric oxide synthase-selective inhibitor. Carcinogenesis (Lond.), 21: 617-621, 2000.
8. Rao, C. V., Cooma, I., Simi, B., Manning, P. T., Connor, J. R., and Reddy, B. S. Chemopreventive properties of a selective inducible nitric oxide synthase inhibitor in colon carcinogenesis, administered alone or in combination with celecoxib, a selective cyclooxygenase-2 inhibitor. Cancer Res., 62: 165-170, 2002.
9. Reddy, B. S., Rao, C. V., and Seibert, K. Evaluation of cyclooxygenase-2 inhibitor for potential chemopreventive properties in colon carcinogenesis. Cancer Res., 56: 4566-4569, 1996.
10. Jones, D. A., Carlton, D. P., McIntyre, T. M., Zimmerman, G. A., and Prescoll, S. M. Molecular cloning of human prostaglandin endoperoxide synthase type-II and demonstration of expression in response to cytokines. J. Biol. Chem., 268: 9049-9054, 1993.
11. DuBois, R. N., Abramson, S. B., Crofford, L., Gupta, R. A., Simon, L. S., Leo, B. A., and Lipsky, P. E. Cyclooxygenase in biology and disease. FASEB J., 12: 1063-1073, 1998.
12. Giardiello, F. M., Hamilton, S. R., Krush, A. J., Piantoadosi, S., Hylind, L. M., Celano, P., Booker, S. V., Robison, C. R., and Offerhaus, G. J. Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis. N. Engl. J. Med., 328: 1313-1316, 1993.
13. Grosch, S., Tegeder, I., Niederberger, E., Brautigam, L., and Geisslinger, G. COX-2 independent induction of cell cycle arrest and apoptosis in colon cancer cells by the selective COX-2 inhibitor celecoxib. FASEB J., 14: 2742-2744, 2001.
14. Smith, M. L., Hawcroft, G., and Hull, M. A. The effect of non-steroidal antiinflammatory drugs on human colorectal cancer cells: evidence of different mechanisms of action. Eur. J. Cancer, 36: 664-674, 2000.
15. Giaccio, A. J., and Kastan, M. B. The complexity of p53 modulation: emerging patterns from divergent signals. Genes Dev., 12: 2973-2983, 1998.
16. Lakin, N. D., and Jackson, S. P. Regulation of p53 in response to DNA damage. Oncogene, 18: 7644-7655, 1999.
17. Micheal, B. K., and Gerard, P. Z. Parc-ing p53 in the cytoplasm. Cell, 112: 1-5, 2003.
18. El-Deiry, W. S. Regulation of p53 downstream genes. Semin. Cancer Biol., 8: 345-357, 1998.
19. Xiong, Y., Hannon, G. J., Zhang, H., Casso, D., Kobayashi, R., and Beach, D. p21 is a universal inhibitor of cyclin kinases. Nature (Lond.), 366: 701-704, 1993.
20. Lane, D. P. Cancer. P53, guardian of the genome. Nature (Lond.), 358: 15-16, 1992.
21. Vogelstein, B., and Kinzler, K. W. p53 function and dysfunction. Cell, 70: 523-526, 1992.
22. Agarwal, M. L., Taylor, W. R. Chernov, M. V., Chernova, O. B., and Stark, G. R. The p53 network. J. Biol. Chem., 273: 1-4, 1998.
23. Moll, U. M., Laquaglia, M., Benard, J., and Riou, G. Wild-type p53 protein undergoes cytoplasmic sequestration in undifferentiated neuroblastomas but not in differentiated tumors. Proc. Natl. Acad. Sci. USA, 92: 4407-4411, 1995.
24. Issacs, J. S., Hardman, R., Carman, T. A., Barrnet, J. C., and Weissman, B. E. Differential subcellular p53 localization and function in N- and S-type neuroblastoma cell lines. Cell Growth Differ., 9: 545-555, 1998.
25. Tominaga, O., Hamelin, R., Trouvat, V., Salmon, R. J., Lesec, G., Thomas, G., and Remvikos, Y. Frequently elevated content of immunochemically defined wild-type p53 protein in colorectal adenomas. Oncogene, 8: 2653-2658, 1993.
26. Moos, P. J., Edes, K., and Fitzpatrick, F. A. Inactivation of wild-type p53 tumor suppressor by electrophilic prostaglandins. Proc. Natl. Acad. Sci. USA, 97: 9215-9220, 2000.
27. Swamy, M. V., Cooma, I., Reddy, B. S., and Rao, C. V. Lamin B, caspase-3 activity, and apoptosis induction by a combination of HMG-CoA reductase inhibitor and COX-2 inhibitors: a novel approach in developing effective chemopreventive regimens. Int. J. Oncol., 20: 753-759, 2002.
28. Swamy, M. V., Cooma, I., J. M. R. Patlolla, Simi, B., Reddy, B. S., and Rao, C. V. Chemoprevention of colon cancer by modulation of COX-2 expression and activity: Development of novel chemoprevention regimens. Proced. Am. Assoc. Cancer Res., 44: 974-975, 2003.
29. Moos, P. J., Edes, K., Cassidy, P., Massuda, E., and Fitzpatrick, F. A. Electric prostaglandins and lipid aldehydes repress redox-sensitive transcription factors p53 and hypoxia-inducible factor by impairing the sclenoprotein thioredoxin reductase. J. Biol. Chem., 278: 745-750, 2003.
30. Sohn, K. J., Choi, M., Song, J., Chan, S., Medline, A., Gallinger, S., and Kim, Y. I. Msh2 deficiency enhances somatic apc and p53 mutations in apc +/- msh2-/- mice. Carcinogenesis, 22: 217-224, 2003.
31. Bosari, S., Viale, G., Roncalli, M., Graziani, D., Borsani, G., Lee, A. K., and Coggi, G. p53 gene mutations, p53 protein accumulation and compartmentalization in colorectal adenocarcinoma. Am. J. Pathol., 147: 790-798, 1995.
32. Honn, K. V., and Marnett, L. J. Requirement of a reactive alpha, beta-unsaturated carbonyl for inhibition of tumor growth and induction of differentiation by "A" series prostaglandins. Biochem. Biophys. Res. Commun., 129: 34-40, 1985.
33. Fitzpatrick, F. A. Inflammation, carcinogenesis and cancer. Int. Immunopharmacol., 1: 1651-1667, 2001.
34. Moll, U. M., Riou, G., and Levine, A. J. Two distinct mechanisms alter p53 in breast cancer: mutation and nuclear exclusion. Proc. Natl. Acad. Sci. USA, 89: 7262-7266, 1992.
35. Umansky, V., and Schirrmacher, V. Nitric oxide-induced apoptosis in tumor cells. Adv. Cancer Res., 82: 107-131, 2001.